D. E. Shaw & Co., Inc. Axogen, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Axogen, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 448,433 shares of AXGN stock, worth $7.19 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
448,433
Previous 562,426
20.27%
Holding current value
$7.19 Million
Previous $10.4 Million
53.24%
% of portfolio
0.0%
Previous 0.01%
Shares
32 transactions
Others Institutions Holding AXGN
# of Institutions
169Shares Held
40.2MCall Options Held
69.1KPut Options Held
0-
First Light Asset Management, LLC Edina, MN4.53MShares$72.6 Million7.55% of portfolio
-
Black Rock Inc. New York, NY3.25MShares$52.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.73MShares$43.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.51MShares$40.3 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.93MShares$31 Million0.03% of portfolio
About Axogen, Inc.
- Ticker AXGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 42,283,700
- Market Cap $678M
- Description
- AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...